356 related articles for article (PubMed ID: 17191072)
1. Targeting interferon-alpha increases antitumor efficacy and reduces hepatotoxicity of E1A-mutated spread-enhanced oncolytic adenovirus.
Shashkova EV; Spencer JF; Wold WS; Doronin K
Mol Ther; 2007 Mar; 15(3):598-607. PubMed ID: 17191072
[TBL] [Abstract][Full Text] [Related]
2. Targeting Interferon-α Increases Antitumor Efficacy and Reduces Hepatotoxicity of E1A-mutated Spread-enhanced Oncolytic Adenovirus.
Shashkova EV; Spencer JF; Wold WS; Doronin K
Mol Ther; 2007 Mar; 15(3):598-607. PubMed ID: 28182898
[TBL] [Abstract][Full Text] [Related]
3. Anticancer activity of oncolytic adenovirus vector armed with IFN-alpha and ADP is enhanced by pharmacologically controlled expression of TRAIL.
Shashkova EV; Kuppuswamy MN; Wold WS; Doronin K
Cancer Gene Ther; 2008 Feb; 15(2):61-72. PubMed ID: 17992200
[TBL] [Abstract][Full Text] [Related]
4. HCCS1-armed, quadruple-regulated oncolytic adenovirus specific for liver cancer as a cancer targeting gene-viro-therapy strategy.
Xu HN; Huang WD; Cai Y; Ding M; Gu JF; Wei N; Sun LY; Cao X; Li HG; Zhang KJ; Liu XR; Liu XY
Mol Cancer; 2011 Nov; 10():133. PubMed ID: 22040050
[TBL] [Abstract][Full Text] [Related]
5. Tumor-specific, replication-competent adenovirus vectors overexpressing the adenovirus death protein.
Doronin K; Toth K; Kuppuswamy M; Ward P; Tollefson AE; Wold WS
J Virol; 2000 Jul; 74(13):6147-55. PubMed ID: 10846098
[TBL] [Abstract][Full Text] [Related]
6. An oncolytic adenovirus selective for retinoblastoma tumor suppressor protein pathway-defective tumors: dependence on E1A, the E2F-1 promoter, and viral replication for selectivity and efficacy.
Jakubczak JL; Ryan P; Gorziglia M; Clarke L; Hawkins LK; Hay C; Huang Y; Kaloss M; Marinov A; Phipps S; Pinkstaff A; Shirley P; Skripchenko Y; Stewart D; Forry-Schaudies S; Hallenbeck PL
Cancer Res; 2003 Apr; 63(7):1490-9. PubMed ID: 12670895
[TBL] [Abstract][Full Text] [Related]
7. A novel oncolytic adenovirus targeting Wnt signaling effectively inhibits cancer-stem like cell growth via metastasis, apoptosis and autophagy in HCC models.
Zhang J; Lai W; Li Q; Yu Y; Jin J; Guo W; Zhou X; Liu X; Wang Y
Biochem Biophys Res Commun; 2017 Sep; 491(2):469-477. PubMed ID: 28698142
[TBL] [Abstract][Full Text] [Related]
8. Anti-tumor activity of a miR-199-dependent oncolytic adenovirus.
Callegari E; Elamin BK; D'Abundo L; Falzoni S; Donvito G; Moshiri F; Milazzo M; Altavilla G; Giacomelli L; Fornari F; Hemminki A; Di Virgilio F; Gramantieri L; Negrini M; Sabbioni S
PLoS One; 2013; 8(9):e73964. PubMed ID: 24069256
[TBL] [Abstract][Full Text] [Related]
9. A hepatocellular carcinoma-specific adenovirus variant, CV890, eliminates distant human liver tumors in combination with doxorubicin.
Li Y; Yu DC; Chen Y; Amin P; Zhang H; Nguyen N; Henderson DR
Cancer Res; 2001 Sep; 61(17):6428-36. PubMed ID: 11522637
[TBL] [Abstract][Full Text] [Related]
10. A simplified system for generating oncolytic adenovirus vector carrying one or two transgenes.
Hu ZB; Wu CT; Wang H; Zhang QW; Wang L; Wang RL; Lu ZZ; Wang LS
Cancer Gene Ther; 2008 Mar; 15(3):173-82. PubMed ID: 18157145
[TBL] [Abstract][Full Text] [Related]
11. Viral genome DNA/lipoplexes elicit in situ oncolytic viral replication and potent antitumor efficacy via systemic delivery.
Kwon OJ; Kang E; Kim S; Yun CO
J Control Release; 2011 Oct; 155(2):317-25. PubMed ID: 21699929
[TBL] [Abstract][Full Text] [Related]
12. Conditionally replicative adenovirus driven by the human telomerase promoter provides broad-spectrum antitumor activity without liver toxicity.
Irving J; Wang Z; Powell S; O'Sullivan C; Mok M; Murphy B; Cardoza L; Lebkowski JS; Majumdar AS
Cancer Gene Ther; 2004 Mar; 11(3):174-85. PubMed ID: 14726958
[TBL] [Abstract][Full Text] [Related]
13. Increased safety with preserved antitumoral efficacy on hepatocellular carcinoma with dual-regulated oncolytic adenovirus.
Zhang Q; Chen G; Peng L; Wang X; Yang Y; Liu C; Shi W; Su C; Wu H; Liu X; Wu M; Qian Q
Clin Cancer Res; 2006 Nov; 12(21):6523-31. PubMed ID: 17085667
[TBL] [Abstract][Full Text] [Related]
14. Systemic toxicity-efficacy profile of ICOVIR-5, a potent and selective oncolytic adenovirus based on the pRB pathway.
Cascallo M; Alonso MM; Rojas JJ; Perez-Gimenez A; Fueyo J; Alemany R
Mol Ther; 2007 Sep; 15(9):1607-15. PubMed ID: 17579575
[TBL] [Abstract][Full Text] [Related]
15. E1A- and E1B-Double mutant replicating adenovirus elicits enhanced oncolytic and antitumor effects.
Kim J; Kim JH; Choi KJ; Kim PH; Yun CO
Hum Gene Ther; 2007 Sep; 18(9):773-86. PubMed ID: 17725410
[TBL] [Abstract][Full Text] [Related]
16. Etoposide enhances antitumor efficacy of MDR1-driven oncolytic adenovirus through autoupregulation of the MDR1 promoter activity.
Su BH; Shieh GS; Tseng YL; Shiau AL; Wu CL
Oncotarget; 2015 Nov; 6(35):38308-26. PubMed ID: 26515462
[TBL] [Abstract][Full Text] [Related]
17. Radiation increases the activity of oncolytic adenovirus cancer gene therapy vectors that overexpress the ADP (E3-11.6K) protein.
Toth K; Tarakanova V; Doronin K; Ward P; Kuppuswamy M; Locke JE; Dawson JE; Kim HJ; Wold WS
Cancer Gene Ther; 2003 Mar; 10(3):193-200. PubMed ID: 12637940
[TBL] [Abstract][Full Text] [Related]
18. Immune gene-viral therapy with triplex efficacy mediated by oncolytic adenovirus carrying an interferon-gamma gene yields efficient antitumor activity in immunodeficient and immunocompetent mice.
Su C; Peng L; Sham J; Wang X; Zhang Q; Chua D; Liu C; Cui Z; Xue H; Wu H; Yang Q; Zhang B; Liu X; Wu M; Qian Q
Mol Ther; 2006 May; 13(5):918-27. PubMed ID: 16497559
[TBL] [Abstract][Full Text] [Related]
19. E1A, E1B double-restricted adenovirus with RGD-fiber modification exhibits enhanced oncolysis for CAR-deficient biliary cancers.
Wakayama M; Abei M; Kawashima R; Seo E; Fukuda K; Ugai H; Murata T; Tanaka N; Hyodo I; Hamada H; Yokoyama KK
Clin Cancer Res; 2007 May; 13(10):3043-50. PubMed ID: 17505007
[TBL] [Abstract][Full Text] [Related]
20. A survivin-mediated oncolytic adenovirus induces non-apoptotic cell death in lung cancer cells and shows antitumoral potential in vivo.
Li B; Liu X; Fan J; Qi R; Bo L; Gu J; Qian Q; Qian C; Liu X
J Gene Med; 2006 Oct; 8(10):1232-42. PubMed ID: 16900558
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]